Navigation Links
Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
Date:9/13/2010

strong results from both Preclinical eValuation and Personalized Oncology.  In addition, with the hiring of our Preclinical Sales Director in August 2010, we are positioned to reach out to more pharmaceutical companies that can utilize our Preclinical eValuation platform."

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs.  The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor.  The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials.  As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate.  The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to Companies for evaluation of oncology drugs and drug candidates in models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized tr
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
2. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
3. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
4. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
5. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
6. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
7. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
8. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
9. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
10. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
11. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Cytokinetics, Incorporated ... report first quarter results on Thursday, April 30, 2015 ... senior management will host a conference call at 4:30 ... and the company’s outlook for the future. , The ... accessed from the homepage and in the Investor Relations ...
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: ... second quarter financial results on Thursday, August 6, 2009. OncoGenex ... p.m. EDT that afternoon to discuss quarterly results. , The ... the OncoGenex Web site at www.oncogenex.com . Alternatively, you ...
... ... Training Programme (JWTP) in India from October 6-10, 2009" is all set ... Jatropha and other Oil Crop Projects, Programmes and Priorities to Feed Biodiesel ... last year,s event, and a number of alternative feedstocks emerged over the ...
... ... MicroFuelerTM Installation , ... CA (PRWEB) August 1, 2009 -- The future of filling up your tank at home ... into a high performance ethanol fuel for cars was installed Thursday night at a home ...
Cached Biology Technology:Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 2Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 3Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 4America's Organic Home-Fueling Movement Begins in Los Angeles 2America's Organic Home-Fueling Movement Begins in Los Angeles 3
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... advocates will gather at Arizona State University for the ... 16-18, 2011. The conference will be a premier ... new approach to battling cancer: the development of ... disease. Despite 40 years since the "War on ...
... (IOF) and the World Health Organization Collaborating Centre for Metabolic ... launch of a FRAX calculator for Singapore. The ... been developed by the WHO to help evaluate patients at ... clinical risk factors, with or without the use of bone ...
... a major cause of plant diseases and are responsible ... other cereals all over the world. Together with scientists ... the Max Planck Institute for Terrestrial Microbiology in Marburg, ... University of Gttingen, analysed the genetic make-up of Sporisorium ...
Cached Biology News:Experts converge at Arizona State University for first preventive cancer vaccine conference 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2Evolutionary arms race between smut fungi and maize plants 2Evolutionary arms race between smut fungi and maize plants 3
Viral CCI Biotinylated Affinity Purified PAb...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Biology Products: